skip to main content

This content will become publicly available on February 26, 2016

Title: Potent human α-amylase inhibition by the β-defensin-like protein helianthamide

Here, selective inhibitors of human pancreatic α-amylase (HPA) are an effective means of controlling blood sugar levels in the management of diabetes. A high-throughput screen of marine natural product extracts led to the identification of a potent (Ki = 10 pM) peptidic HPA inhibitor, helianthamide, from the Caribbean sea anemone Stichodactyla helianthus. Active helianthamide was produced in Escherichia coli via secretion as a barnase fusion protein. X-ray crystallographic analysis of the complex of helianthamide with porcine pancreatic α-amylase revealed that helianthamide adopts a β-defensin fold and binds into and across the amylase active site, utilizing a contiguous YIYH inhibitory motif. Helianthamide represents the first of a novel class of glycosidase inhibitors and provides an unusual example of functional malleability of the β-defensin fold, which is rarely seen outside of its traditional role in antimicrobial peptides.
 [1] ;  [2] ;  [2] ;  [2] ;  [2] ;  [2] ;  [2] ;  [2] ;  [1] ;  [1] ;  [2] ;  [2] ;  [3]
  1. Michael Smith Lab., Vancouver, BC (Canada)
  2. Univ. of British Columbia, Vancouver, BC (Canada)
  3. Michael Smith Lab., Vancouver, BC (Canada); Univ. of British Columbia, Vancouver, BC (Canada)
Publication Date:
OSTI Identifier:
Grant/Contract Number:
111082; AC02-76SF00515; P41GM103393
Published Article
Journal Name:
ACS Central Science
Additional Journal Information:
Journal Volume: 2; Journal Issue: 3; Journal ID: ISSN 2374-7943
American Chemical Society (ACS)
Research Org:
SLAC National Accelerator Lab., Menlo Park, CA (United States)
Sponsoring Org:
USDOE Office of Science (SC), Biological and Environmental Research (BER) (SC-23); USDOE Office of Science (SC), Basic Energy Sciences (BES) (SC-22)
Country of Publication:
United States